A service of StreetInsider.com
Ticker Symbol

Most Popular

AAPL 98.15
GOOG 587.42
MSFT 43.58
BAC 15.58
FB 74.68

Recently Added

GEVO 0.72
SONS 3.67
BRK-B 127.74
PSX 81.72
P 25.98

Gaining Speed

GEVO 0.72
SONS 3.67
WPCS 1.08
UEC 1.71
DARA 1.34

ZIOPHARM Oncology (ZIOP) Reports Palifosfamide Hits PFS Events in Phase 3

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that the Phase 3 (PICASSO 3) trial of palifosfamide (ZIO-201) in first-line metastatic soft tissue sarcoma has reached its target number of progression-free survival (PFS) events. PICASSO 3 is an international, randomized, double-blind, placebo-controlled trial whose primary endpoint is PFS....

Read More

Get Alerted When News Hits On This Stock - FREE!